Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Well preserved versus severely impaired memory 10-44 years after temporal lobe epilepsy surgery: "How did the patients get there?"

Seizure·2026
Same author

Executive dysfunction and employment in epilepsy.

Epilepsia·2026
Same author

Brain MRI findings in patients with post COVID-19 condition: frequency and longitudinal changes in a nationwide cohort study.

Frontiers in neurology·2025
Same author

Epilepsy and marriage - the story of the abolition of laws that discriminated people with epilepsy in Norway.

Seizure·2025
Same author

Seizure classification using a multimodal seizure monitoring system (Nelli) in Dravet and Lennox-Gastaut syndromes: A non-randomized, single-center feasibility study.

Epilepsia·2025
Same author

Syndromic and etiological classification predicts seizure freedom in childhood and youth onset epilepsy: A population-based study from the Norwegian Mother, Father, and Child Cohort Study.

Epilepsia·2025
Same journal

A woman in her 70s with chest pain and elevated troponin T levels.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Ductus arteriosus aneurysm in a neonate with inspiratory stridor.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same journal

Confined to a lunatic asylum for eleven years: the case of Haaken Bergh.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

[Polyunsaturated fatty acids and epilepsy].

Anette Huuse Farmen1, Morten I Lossius, Karl O Nakken

  • 1Nevrologisk avdeling Sykehuset Innlandet Lillehammer Anders Sandviks gate 17 2609 Lillehammer. anette.huuse.farmen@sykehuset-innlandet.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|January 3, 2009
PubMed
Summary
This summary is machine-generated.

Polyunsaturated fatty acids show promise for treating epilepsy, with animal studies indicating reduced seizures. However, more human clinical trials are needed to confirm their effectiveness as an epilepsy treatment.

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
08:26

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

Related Experiment Videos

Last Updated: Jun 26, 2026

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
08:26

Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy

Published on: October 19, 2021

Area of Science:

  • Neurology
  • Biochemistry
  • Dietary Science

Background:

  • Epilepsy affects 30% of patients with recurrent, drug-resistant seizures.
  • Ketogenic diets have shown positive effects in children with catastrophic epilepsy.
  • Polyunsaturated fatty acids (PUFAs) are implicated in the anticonvulsant properties of ketogenic diets.

Purpose of the Study:

  • To review the potential of polyunsaturated fatty acids (PUFAs) as an epilepsy treatment.
  • To explore the biochemical mechanisms underlying the anticonvulsive effects of PUFAs.

Main Methods:

  • A non-systematic literature search was conducted using Cochrane and PubMed databases (pre-June 2008).
  • Keywords included: epilepsy, polyunsaturated fatty acids, clinical trials, ketogenic diet, and treatment.
  • Focus was on articles with clinical aspects and laboratory research.

Main Results:

  • Animal studies suggest PUFAs can reduce seizure likelihood via biochemical pathways.
  • Evidence for PUFAs having direct antiepileptic effects in humans is currently insufficient.
  • Ketogenic diet studies were sourced from Cochrane, while clinical and lab research came from PubMed.

Conclusions:

  • While animal studies are promising, human data on PUFAs for epilepsy treatment is limited.
  • Further clinical research is necessary to establish PUFAs as a viable epilepsy therapy.
  • The role of PUFAs in epilepsy warrants continued investigation.